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Abstract
Background: One of the most important developments in bioinformatics over the past few
decades has been the observation that short linear peptide sequences (minimotifs) mediate many
classes of cellular functions such as protein-protein interactions, molecular trafficking and posttranslational modifications. As both the creators and curators of a database which catalogues
minimotifs, Minimotif Miner, the authors have a unique perspective on the commonalities of the
many functional roles of minimotifs. There is an obvious usefulness in standardizing functional
annotations both in allowing for the facile exchange of data between various bioinformatics
resources, as well as the internal clustering of sets of related data elements. With these two
purposes in mind, the authors provide a proposed syntax for minimotif semantics primarily useful
for functional annotation.
Results: Herein, we present a structured syntax of minimotifs and their functional annotation. A
syntax-based model of minimotif function with established minimotif sequence definitions was
implemented using a relational database management system (RDBMS). To assess the usefulness of
our standardized semantics, a series of database queries and stored procedures were used to
classify SH3 domain binding minimotifs into 10 groups spanning 700 unique binding sequences.
Conclusion: Our derived minimotif syntax is currently being used to normalize minimotif covalent
chemistry and functional definitions within the MnM database. Analysis of SH3 binding minimotif
data spanning many different studies within our database reveals unique attributes and frequencies
which can be used to classify different types of binding minimotifs. Implementation of the syntax in
the relational database enables the application of many different analysis protocols of minimotif data
and is an important tool that will help to better understand specificity of minimotif-driven
molecular interactions with proteins.

Background
Minimotifs (also called Short Linear Motifs [SLIMs]), are
short peptide sequences which play important roles in

many cellular functions [1-3]. Many minimotif databases
such as Minimotif Miner (MnM), Eukaryotic Linear Motif
(ELM), phospho.ELM, DOMINO, MEROPS, PepCyber
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and HPRD have cataloged more than a thousand minimotif entries and are expected to have significant growth in
the near future [1,4-10]. Each of these databases model
functional minimotifs in some capacity, often using individualized annotation schemes useful for the subset of
minimotif data being managed. As the amount of minimotif data continues to grow, there are several expected
advantages to be gained from the use of a standardized
syntax. A standardized syntax will facilitate exchange of
data with different minimotif databases. Likewise, a
standardized syntax will allow integration with other nonmotif databases enabling researchers to examine the connection of minimotifs with new types of data (e.g. disease
mutations, protein structures, cellular activities, etc.), providing new opportunities for data mining. A standardized
syntax will also allow refinement of minimotif sequence
definitions, reduce redundant data, and normalize future
annotation efforts.
The authors have been the curators of the Minimotif
Miner database for the past four years. In compiling and
managing this large dataset, we have had a lengthy and
detailed exposure to the functional annotations currently
reported in the scientific literature. This unique perspective has afforded us the insight as to certain common features of the functional annotation of minimotifs. Here we
propose a standardized definition for minimotifs that is
currently being used within MnM and which can be
broadly applied to all minimotifs including those in the
aforementioned databases.
We have observed that all minimotif annotations are
composed of two major categories, the covalent chemistry
and the function of the peptide. The first component of a
minimotif definition includes its sequence and modification information. Schemes for modeling the sequence of
minimotifs are well established and have been adopted
from previous work modeling protein domains[11,12].
The protein sequences of minimotif instances are
sequence strings of amino acids represented using an
alphabet of IUPAC single letter code amino acid abbreviations [13]. For example, the 'PKTPAK' sequence in Kalirin describes an instance or single occurrence of a
minimotif. Higher level minimotif abstractions are often
represented as consensus sequences or position specific
scoring matrices (PSSMs). Consensus sequence definitions identify permissible positional degeneracy. PxxPxK
is an example of consensus definition that describes multiple instances for proteins that bind to the SH3 domain
of Crk; 'x' indicates that any of the 20 amino acids are
allowed at the indicated position. Degeneracy can also be
indicated for groups of amino acids that have similar
chemical properties represented by a set of Greek symbols
[14]. Consensus sequences can be represented as regular
expressions in PROSITE syntax [12]. Probability-based
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PSSMs, like consensus sequences, represent the degeneracy at each position, but have the advantage that the probability of an amino acid at each position is explicit. PSSM
are commonly represented as LOGO plots [15,16].
The sequence definitions described above, by themselves,
have been found to be insufficient to describe many minimotifs which require additional covalent chemical modification. A set of rules for indicating post-translational
modifications was previously defined by the Seefeld Convention [14]. One such rule is to indicate a phosphorylated residue by a lower case 'p' preceding an amino acid
(e.g. RSxpSxP indicates the second Ser is phosphorylated
in this 14-3-3 binding minimotif [17]). In our experience
there are two important limitations imposed by the
Seefeld Convention. First, the forced distinction between
lowercase and uppercase character sets puts undesirable
constraints on the implementation hardware/software;
likewise the use of Greek characters to indicate degeneracy
of amino acids with similar physical properties in minimotif definitions can also be problematic due to machinespecific character encoding. Second, this minimotif syntax
is not extensible to all of the approximately 500 known
posttranslational modifications, several of which have
established roles in minimotif function [14,18]. For
example, myristoylated residues and cis-proline bonds
can not be enumerated using the Seefeld Convention. In
this paper, we describe a model that overcomes these limitations for minimotif sequence definitions.
The second component of minimotifs is their biological
function(s), which have generally been free-form descriptions in minimotif databases with no set standard. To our
knowledge this minimotif subdomain of knowledge has
not yet been modeled, which limits the ability to integrate
data from different databases and hence their global usefulness. There are several ontologies that address domains
related to minimotifs. The Gene Ontology (GO) defines a
vocabulary for molecular and cellular functions and the
association of these functions with gene products. While
this ontology provides a useful resource for functional
activities, the GO database is not designed to describe
minimotif functions, nor capture important common
attributes that are specific to minimotifs [19]. For example, the bind function in GO does not indicate the residues involved in an interaction, nor if any of these
residues require any post-translational modifications.
Likewise, the Protein Ontology, PSI-MOD, and RefSeq
databases help to define entities that can be used for modeling minimotifs but are not sufficient by themselves for
this purpose [20,21].
We provide a standardized semantic and syntactic definition of minimotifs gleaned from the data contained
within MnM 2, and have executed its implementation by

Page 2 of 13
(page number not for citation purposes)

BMC Genomics 2009, 10:360

http://www.biomedcentral.com/1471-2164/10/360

refactoring approximately 5000 minimotif annotations
within MnM. As an example of the utility of this model
and syntax, we demonstrate the use of the new database
in classifying SH3 binding minimotifs.

geranyl gernaylates, cleaves etc The 'Traffics' Activity
describes minimotif sequences required for a protein to be
shuttled between cell compartments or other specific locations within or outside of cells.

Results

In a number of minimotifs, a Minimotif and Activity are
known, but the Target has not yet been identified or it is
not yet known if the interaction of the Minimotif with the
Target is direct. This information is still useful, thus we utilize a 'Required' Activity category which indicates that a
minimotif sequence is necessary for a molecular or cellular activity. For example, the PNAY minimotif in Crk is
required for Abl kinase activation [27]. In this case, Abl
kinase activation is a subcategory of 'Required'. As in this
example, the Target is null for the 'Required' Activity.

Minimotif Function Elements
A disambiguated and extensible semantic basis for minimotif functionality was derived from a set of rules which
characterizes the approximately 5000 minimotifs in the
Minimotif Miner (MnM) database [1] without information loss. We have not created a formal grammar, but
rather a set of rules that characterize minimotif descriptions. For any minimotif clause, the syntax is Minimotif
(subject), Activity (verb), and Target (object) which can be
derived from a set of rules. We define these three major
elements as follows:

Minimotifs consist of sequence definitions and sources.
The sequence definition can be an instance, a consensus
sequence, or a PSSM; all three classes of minimotifs are
commonly reported in the literature. Instances represent
primary data, whereas consensus sequences and PSSMs
are interpretations of the data. Minimotifs may require one
or more post-translation modifications such as phosphorylation or proline isomerization. In each motif, these
modifications can be described by one or more residue
names, type(s) of modification, and position(s) in the
Minimotif sequence. Another approach for modeling residue modifications could be the atomic model previously
described [22]. A source is the protein or peptide that contains the minimotif sequence. For example, in ' [PKTPAK
in Kalirin] [binds] [Crk]', 'PKTPAK' is a sequence definition and 'Kalirin' is the minimotif source [23]. Alternatively, PxxPxK is a consensus definition that describes a
consensus sequence for multiple instances.
Targets are proteins, nucleic acids, carbohydrates, lipids,
small molecules, elements, metals, drugs, or complexes.
In the case of proteins and nucleic acids, Targets may be
associated with sequence definitions. Target proteins may
contain domains as defined by the Conserved Domain
Database [24], belong to a hierarchical classification
based on fold [25] or refer to determined structure elements [26]. In the above example of the PKTPAK minimotif, the Target 'Crk' can be expanded to be more specific
'1st SH3 domain of Crk'; referring to the N-terminal of
two SH3 domains in Crk.
Activities are the actions of minimotifs and all minimotif
activities can be generally classified as binds, modifies or
traffics. The 'Binds' Activity describes an interaction of a
protein containing a minimotif with another molecule.
The 'Modifies' Activity defines a chemical change to a minimotif sequence that can be further subcategorized into
enzymatic activities such as phosphorylates, amidates,

Minimotif Syntax
In order to combine these major minimotif elements and
the minimotif sequence definition into human-interpretable semantic sentences we have defined 22 different
attributes of minimotifs (Table 1) and derived the set of
syntax rules listed below. Our goal was to identify a minimal set of rules that combine minimotif elements in
order to regenerate valid minimotif sentences for the
~5000 minimotifs in the Minimotif Miner database. Valid
minimotif sentences are based on these syntax rules, and
biological entity categories of innumerable size (i.e. protein domains, protein names, molecule names, etc.).
Syntax Rules
Format: Minimotif elements in quotes are variable and
defined in Table 1. Additional definitions are shown in
Table 2. Bold text does not change and italicized elements
are optional. Each minimotif function conforms to one of
four rules (binds, modified, traffics, required).

'Minimotif' = 'Minimotif Sequence' ('Required Modification') in 'Peptide' OR 'Protein'
'Protein target' = 'Domain position' 'domain' domain of'
'Protein'
'Target' = 'Molecule' OR 'Protein target'
'Required modification' = 'Amino acid' 'Position' residue is 'posttranslational modification'
'Activity modification' = 'Amino acid' 'Position' residue
is 'posttranslational modification'
BIND RULE: 'Minimotif' binds 'Target'
MODIFICATION RULE: 'Minimotif' is modified by the
'enzyme activity' of the 'Protein target' ('activity modification').
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Table 1: Attributes of a minimotif definition

#

Attribute1

Valid values and description

1

Motif sequence type

(Consensus, instance, PSSM) type of sequence definition

2

Motif sequence

Any consensus, instance, or PSSM describing a minimotif protein sequence

3

Required modification

description of chemical change to minimotif sequence

4

Motif source name

The name of protein or peptide that contains the minimotif

5

Motif source accession number Swiss-Prot, RefSeq accession numbers for protein sequences containing the minimotif

6

Motif start position

Integer start position of the minimotif in motif source accession number

7

Motif source type

(Peptide and/or protein) indicates whether minimotif was investigated as a peptide fragment or in a protein
domain

8

Activity

(binds, modifies, requires, traffics) the action of the minimotif

9

Subactivity

A more detailed description

10 Activity modification

Description of activity that covalently changes a minimotif sequence

11 Target name

The name of the molecule that acts upon the minimotif

12 Target accession number

If the target is a protein, the Swiss-Prot or RefSeq accession number(s) for Target protein sequence(s). The
target can be a complex

13 Target type

(Peptide and/or protein) indicates whether Target was investigated as a peptide fragment or in a protein
domain

14 Target domain

(any domain in the CDD) protein domain in the minimotif Target

15 Target domain position

Integer that indicates the relative location of a domain relative to its N-terminus for proteins that have more
than one copy of the same domain

16 Target site

Integer for site where a minimotif binds a molecule, if more than one site is known

17 Subcellular localization

Region of the cell where the minimotif activity occurs

18 Affinity

(Kd, IC50, Km) measurement of affinity of minimotif for its target

19 Structure

(PDB accession number) for a structure of the minimotif in complex with its target. A related attribute is
'related structures' of the minimotif source or target.

20 Experimental evidence

(X-ray, NMR, Phage display, peptide mapping, alanine scanning mutagenesis, evolutionary conservation,
mutagenesis, modeling, deletion mapping, peptide binding, peptide competition, full-length protein, Surface
Plasmon Resonance, ITC, SPOT array, Far-western, Co-immunoprecipitation, yeast 2-hyrbid, pulldown)
different types of experimental evidence that supports a minimotif sentence.

21 Minimotif reference

(PubMed identifier or PDB accession number) indicates the references source(s) of the data supporting the
minimotif definition

22 Database reference

Cross reference ID to other database that contains similar minimotif definition.

11

Attributes are broken up into 4 sections related to the Minimotif (16), Activity (79), Target (1015), and properties (1619) of Motif/Activity/Target
minimotif sentences.

Page 4 of 13
(page number not for citation purposes)

BMC Genomics 2009, 10:360

http://www.biomedcentral.com/1471-2164/10/360

Table 2: Definitions of minimotif elements

Element

Definition

Minimotif

The covalent chemistry of a peptide segment represented by a sequence definition and any required modification and
minimotif source

Minimotif sequence

An instance, consensus sequence, or PSSM that describes a peptide minimotif of less than 15 contiguous residues

Required modification A change in the covalent chemistry of a minimotif sequence
Motif Source

The protein or peptide that contains the motif

Target

The molecule related to a minimotif by an activity

Activity

The action of the minimotif

Binds

Type of activity that involves a direct interaction between two or more molecule species

Modifies

Type of activity where the minimotif has a change in its covalent chemistry

Traffics

Type of activity where a protein moves between cellular compartments

Required

Type of activity where a minimotif is required for a chemical or cellular process

Chemical process

An event that results in a change of covalent bonds on a molecule

Cellular compartment A place in the cell that can be discerned by the localization of at least one molecule
Peptide

Short polymer of amino acids

Protein

Polymer of amino acids

Domain

A region of a protein that folds independently.

Domain position

Location of a domain type in a protein that has more than one copy of a domain type relative to the N-terminus

Cellular process

An event or series of events that results in an observable change in a cell

TRAFFIC RULE: 'Minimotif' is trafficked by 'Target' to
'Cellular compartment' OR 'Minimotif' is trafficked to
'Cellular compartment'
REQUIRED RULE: 'Minimotif' is required for 'Chemical
Process' OR 'Cellular Process'
Syntax Examples
BIND RULE: [IL]xxxxNPxY (tyrosine 497 residue is phosphorylated) in Interleukin 4 receptor binds PTB domain
of IRS-1 [28].

MODIFICATION RULE: GRG in myelin basic protein is
modified by the N arginine methylation activity of
PRMT1 (Arginine 107 is methylated) [29].
TRAFFIC RULE: WHTL in Synaptotagmin is trafficked to
synaptic vesicles [30].

REQUIRED RULE: GKFC in peptide is required for cell
adhesion [31].
Minimotif Model and Implementation
The minimotif syntax was abstracted as a conceptual data
model, which was used to derive logical and physical data
models. An entity-relationship (ER) diagram of our conceptual data model is shown in Figure 1. The primary
objects in the ER diagram are the Minimotif (green), Activities (orange), and Target (Cyan), each of which contains
details regarding their attributes. Each Minimotif has a
sequence and may have a modification (e.g. tyrosine
phosphorylation in BIND RULE). All Minimotifs are in
proteins which may have orthologues and domains. Each
Minimotif can have a Target which is a molecule (Protein,
Nucleic acid and small molecule are molecules; cyan).
Molecules are in cell compartments. The Target has two
relationships with the Minimotif (orange): modifies refers
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Figure 1
Entity-relationship
diagram of a conceptual minimotif data model
Entity-relationship diagram of a conceptual minimotif data model. Activities are colored orange; relationships are
gray; molecules are cyan. There are properties of a Motif/Activity/Target in the database that are not present in this conceptual
diagram.

to a change in chemistry of the Minimotif, thus the Target
is an enzyme in this case (MODIFIES RULE). For example,
a Minimotif that is cut by a protease is chemically modified
by an enzyme. The Target can also bind the Minimotif
(BIND RULE). In the case where a Target molecule is not
known, the Minimotif may be required for some Activity as
in the REQUIRED RULE above. The TRAFFIC RULE is not
represented in this diagram, but a Minimotif is trafficked
by a Target from one cell compartment to another; the Target need not be known for the TRAFFIC RULE.
The physical implementation of the database is shown in
Figure 2. The design of the minimotif relational database
shows an intersection table (motif_source) of the Minimotif, Activity, and Target tables. Each minimotif in the database table has its own specific attributes such as minimotif
type (consensus sequence or instance), a structure from
the Protein Data Bank, an affinity for the Minimotif/Target
complex, and published experimental techniques that
support the Minimotif/Activity/Target relationship.

We have previously reported the MnM 2 database which
contains more than 5000 minimotifs [2]. We have now
refactored the MnM 2 database to use controlled vocabularies. These include the Gene Ontology (GO; the Activity
term names and id's for common molecular functions),
NCBI Taxonomy for id's and species names, NCBI Conserved Domain Database (CDD; the names and identifiers
for protein domains in motif Targets), NCBI Reference
Sequences (RefSeq; for Target and Minimotif source protein names and ids), Human Proteome Organization
(HUPO; for experimental evidence names and id's), PsiMod for post translational modifications of Minimotifs,
and the Protein databank (PDB, for accession numbers for
protein structure files). The new relational database that
uses these controlled vocabularies enforces, normalizes,
integrates, and explicitly defines the minimotif semantics.
Details concerning the database are in Methods.
The minimotifs in the Minimotif Miner (MnM) database
were refactored and implemented in MnM 2 [2]. Our
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Figure
A
physical
2 implementation of the conceptual minimotif data model in MySQL
A physical implementation of the conceptual minimotif data model in MySQL. Relationships between tables are
indicated. Three convergent lines pointing outward from a table indicate its dependency on another table. A circle or bar at the
end of a line indicates that a relationship is optional or mandatory, respectively.

implementation of this model supports an integrative,
semantically-rich minimotif analysis via the Structured
Query Language (SQL), and importantly, is compatible
with external motif analysis algorithms. This implementation enables extraction of groups of Minimotifs which
share common values for any subset or combinations of
subsets for the 22 different attributes in the model (Table
1). A set of 10 rules can be used to regenerate structured
unambiguous human readable annotations [see Additional file 1].
We have built a user interface that enables users to query
this database. This webpage is available as a link from the
MnM 2 website. Users can select identifiers or text based
descriptions from controlled vocabularies to query the
database. For example, all SH3 binding motifs can by
identified by selecting this domain from the CDD controlled vocabulary for domains [24]. Many minimotif
attributes can be queried from this page.

Once the query system is used to retrieve and group primary minimotif data (instances), interpretations of this
data are often the next step in minimotif analysis. The
interpretations of this data most commonly reported in
the literature are consensus sequences, PSSMs, and groupings of families of minimotifs; these can be automatically
generated based on query results generated by the aforementioned query system.
Often a single laboratory does an experiment that identifies a consensus sequence, PSSM or grouping. MnM stores
individual instances as reported in the literature, as well as
inferred consensus sequences as reported by the authors.
Our new query page has the advantage that consensus
sequences, PSSMs or families of motifs can be generated
from user-selected instances from one or more independent studies. Thus, this tool can be used to study groupings,
consensus sequences, and PSSMs, which can vary significantly between different studies. Once groupings of
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instances are selected from the new query page, users can
then generate consensus sequences or PSSMs.
Grouping SH3 Domain Binding Minimotifs
There are many advantages expected to be gained by the
use of a standardized minimotif syntax and query system.
One such advantage is the simplified clustering of data
within the database based on these new syntactical rules.
As a case example, we classified 1363 SH3 binding minimotifs queried from the MnM 2 database. We selected this
collection of data because of both the large number of
reported SH3 binding minimotifs and the growing
number of reported consensus sequences (e.g. PxxP, RxxPxxP, and PxxPxx [KR]). We posed a number of questions
which would have been difficult to address without the
syntax, but which are now easily addressed by querying
the new relational database: Which SH3 consensus
sequences are most common? How many SH3 binding
consensuses are present in different instances? Do SH3
minimotifs bind to the same site? Is there a residue preference for degenerate positions?

A number of these questions had already been answered
in an ad hoc fashion, but our goal in this case study was to
address these questions in a systematic manner. Additional details for this analysis are provided [see Additional
file 1].
The groups of SH3 binders were extracted by custom SQL
statements filtering Minimotifs by type (consensus vs.
instance), Target (SH3 containing proteins), and Activity
(binds). This resulted in 1363 (741 unique) SH3 binding
minimotifs, which could further be segregated into 69
consensus sequences and 672 instances. These sequences
were compared inside our database for similarity based
on the Shannon Information Content similarity metric as
implemented by the Comparimotif library [32]. This analysis resulted in 10 minimotif groups that describe all SH3
binding minimotifs in the database (Figure 3). Details
concerning the clustering analysis, queries, and results
that lead to the distinct minimotif groups are provided
[see Additional file 1].
Structural analysis of SH3 ligands
In order to better understand how these 10 SH3 binding
minimotif groups were related to each other, we analyzed
their known SH3/ligand complex structures. We queried
the Minimotif Miner database and located representative
structures for eight of the 10 groups. The fit function of
Molmol was used to align the backbones of the eight SH3
domains using 6 residues in the β1 sheet, 4 residues in the
310 helix and 6 residues in the β4 sheet [33]. The root
mean squared deviation (RMSD) for alignment of the
backbone residues in these regions was 0.9 Å indicating a
good alignment (Figure 2). We then examined the rela-
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tionships of the binding sites of the different minimotifs
by adding the sidechain bonds of the conserved residue
positions and backbone atoms for each minimotif. For
two structures we were only able to identify the binding
sites based on nuclear magnetic resonance chemical shift
mapping experiments [34,35].
Our analysis revealed that although SH3 domains are
most commonly discussed for their ability to bind PxxP
containing peptides, members of the SH3 domain family
bind several different consensus sequences and have specialized structural interfaces. Of the 10 minimotif groups,
many used different binding pockets on the SH3 domain.
Four minimotifs bound in a similar region to the standard
PxxP binding site (RxxPxxP, BxxB, PxxxPR, and KPTVY).
The BxxB (B = basic) shares only one of two binding pockets with PxxP as previously noted [36,37]. Two of the
motifs (RxxPxxP and PxxxPR) were found to bind in two
different orientations with the peptides flipped ~180° in
the binding sites. Two other consensus sequences bound
previously identified alternative sites not near the PxxP
site, and two had no structural information. This analysis
confirms the distinction of the minimotif clusters derived
by the sequence based-analysis.
Most SH3 domain binding peptides have multiple
consensus sequences
Until recently, BxxB, PxxxPR, and several other types of
SH3 binding minimotifs were not known. Given that
there were 10 different types of SH3 binding consensus
minimotifs, we wanted to know to what extent did previously studied ligands have multiple consensus sequences.
We designed a query (query 9) that assessed how many
consensus sequences were present in each ligand excluding the pairing of PxxP with RxxPxxP and PxxPx [KR]
because these minimotifs are children of PxxP.

The average number of minimotif consensa per SH3 ligand was 2.3 indicating a tendency for each ligand
sequence to have multiple SH3 consensus sequences. In
the most extreme examples the SPTPPPVPRRGTHT,
QPPVPSLPPRNIKP, KKPPPPVPKKPAKS, RRPPVPPR, and
RRAPPPVPKKPAKG ligands each have five of the 10 different SH3 binding consensus sequences. For each consensus sequence, we have also reported the percent
ambiguity in Figure 3 which is the percentage of each minimotif for which there are multiple consensus sequences.
It is obvious from this analysis that a high proportion of
previous SH3 binding experiments assessed ligands with
potential to have multiple ligand binding modes. Thus,
the majority of SH3 binding data may be subject to
ambiguous interpretation (Figure 3). In interpreting many
previous SH3 binding experiments, new ligand binding
modes may now need to be considered in the experimental interpretation. Our database contains only 50 of the
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Figure
SH3
binding
3 minimotif family
SH3 binding minimotif family. SH3 binding minimotifs were grouped into the 10 minimotif categories using the relational
database and Shannon Information Content similarity metric. Surface plots of structures identified for 8 of the 10 group (1ZSG,
black; 1NM7, pink; 1AZE, cyan; 2BZ8, blue; 1CKA, magenta; 1OPL, red; 1RLQ orange; 1H3H, green; 1NYG, brown) are
shown. The carbon backbones of SH3 domains were fit using Molmol with residues in the β1 and β4 sheets, and the 310 helix,
to an RMSD of 0.9 [33]. An overlay of each SH3 domain carbon backbone with its peptide minimotif is color matched and relevant minimotif side chain bonds are represented as thickened lines; the surface plot for the overlay is derived from the 1ZSG
structure). Structures of the ligands for the RKxxYxxY and WxxxFxxLE minimotifs are not known, but the binding sites on the
SH3 domains derived from NMR chemical shift mapping experiments are indicated. RxxPxxP and PxxxPR minimotifs show
structures with the peptides in opposing orientations. The consensus sequences (C), total number of minimotifs for C (M), and
percentage of potentially ambiguous ligand instances (A) in the MnM 2 database are indicated.

270 known human proteins with SH3 domains, thus the
10 SH3 minimotif groups we identified may become even
more complex with a comprehensive analysis of all SH3
domains.
All SH3 domain binding peptides have basic residues
To further characterize the SH3 binding landscape, we
performed analysis of residue content in all SH3 ligands
using queries as described in methods. Compositional
analysis showed a high preference for proline (4.2 fold),
arginine (1.7 fold), and lysine (1.8 fold)(Table 3). In fact,

all SH3 ligands in the database contained either a lysine
or arginine, suggesting that a positive charge may be an
important factor in ligand binding to SH3 domains.
Another study has previously suggested a role for positively charged residues in SH3 domain interactions [38].
Consistent with this observation, the least enriched residues in SH3 ligands were the negatively charged residues.
The overall average calculated charge of SH3-binding peptides in our database was +3.2 ± 1.4 (average length of
12.1 ± 3.1 residues); this calculation is based on summing
Page 9 of 13
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charges of basic and acid residues assuming a neutral pH.
Of nine other groups of minimotifs with common
domain targets in MnM 2 only minimotifs for Calmodulin (n = 31) and 14-3-3 (n = 44) had net positive charges
of 3.0 ± 1.3 and 1.0 ± 0.9, respectively; PDZ (n = 1089),
SH2 (n = 952), kinase (n = 206), PTB (n = 168), protease
(n = 93), FHA (n = 67), WW (n = 27) and phosphatase (n
= 25) domains had ligands or substrates with an average
neutral or net negative charge.
Collectively, these query results strongly suggest that
known SH3 peptide ligands have a more positive overall
charge than proteins in the human proteome. It is important to note that when restricting the SH3 ligand query to
non-BxxB sequences, the average ligand charge was still
+2.2 ± 1.2. Only 11 of the 1363 sequences had a neutral
or negative charge and several of these were for
WxxxFxxLE and PxxDY minimotifs, which have few
instances in the dataset.

Discussion
We have developed a syntax with a set of rules that
describes the more than 5000 minimotifs in the MnM
database. While this syntax is complete for the data currently managed by MnM, we will actively continue to
develop and expand this model to support additional
types of data. The syntax is important because it enables
the use of controlled vocabularies through defined rules,
integration with other types of databases, exchange of
data between minimotif databases, and the ability to
address difficult questions that are facilitated through
mining of minimotif data.

Current approaches for defining the covalent chemistry of
minimotifs are not without limitations, beyond the posttranslational modifications discussed earlier. The most
commonly used representation of a motif is a consensus
sequence. The definition of the word consensus does not
necessitate that all members of a group conform, thus
consensus sequences, while having the advantage that
they can be used to group a number of instances, can also
introduce ambiguity. For example, Calmodulin binding
minimotifs have several members that do not conform to
consensus sequences [39].
We have decided not to model a relationship between
instances and their consensus sequences because these
can be reconstructed through database queries that use a
wider set of data. However, this approach remains to be
tested with rigor and consensus sequences with nonconforming members may prove difficult. There are likely to
be other ways that consensus sequences are limiting, for
example, our SH3 minimotif analysis suggests that this
binding minimotif should have an overall positive charge,
which can not be represented by a consensus sequence.
Furthermore, our semantics currently rely on consensus
sequence definitions and our syntax does not support
PSSMs. While a thorough discussion of sequence definition limitations is beyond the scope of this paper, we
expect that through continued annotation using our
standardized syntax we will able to identify all anomalies
in our model and adjust it accordingly.
Through our work on minimotifs, we recognized a
number of other important limitations that will need to

Table 3: Residue frequencies in SH3 domain ligands

Residue

Total Count

Composition (%)

Enrichment (fold)

A
C
D
E
F
G
H
I
K
L
M
N
P
Q
R
S
T
V
W
Y

554
118
102
100
206
275
54
171
764
697
64
150
2026
200
752
404
310
336
59
102

7.4
1.6
1.4
1.3
2.8
3.7
0.7
2.3
10.2
9.3
0.9
2.0
27.2
2.7
10.1
5.4
4.2
4.5
0.8
1.4

1.0
0.7
0.3
0.2
0.8
0.6
0.3
0.6
1.8
1.0
0.4
0.6
4.2
0.6
1.7
0.7
0.8
0.8
0.7
0.5
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be addressed in the future. Several attributes of minimotifs could be modelled better. For example, some Targets
of motifs are complexes, rather than single proteins. Furthermore, a specific structural conformation of a protein
may be specific to a Minimotif or Target. Wherever possible
we have tried to use controlled vocabularies, but a
number of attributes could expand on this theme. We
could better use vocabularies for activities and subcellular
localizations from the GO database. However, we have
recognized that all minimotif, and perhaps molecular
activities, fit into the general categories of binds, modifies,
or traffics, a basic grouping of function not implemented
in GO. Alias names of proteins also present a problem
with redundancies, but this is a problem endemic to many
biological databases. While many previous minimotif
descriptions in the literature use elements of the syntax we
propose, the syntax is not always structured the same way,
making automated annotation or restructuring of previous literature difficult. Finally, there is no guarantee that
all future minimotif functions we identify will fit in our
model.
We have shown that implementation of the syntax is useful. Our analysis of SH3 binding minimotifs identified
over 1000 minimotifs that cluster into 10 major groups.
The majority of these groups bound to a similar site but,
the specific contacts in the interaction were generally not
conserved between groups. Thus, it seems that while the
evolutionary pressure for binding to the SH3 domain is
strong, the precise mechanism of binding can vary. This
SH3 minimotif analysis emphasizes the necessity of
standardizing minimotif semantics and sequences in a
well-modeled database with a query system that can be
used to manage data from a collection of related studies.
The data-driven classification provides a solution to
grouping minimotifs based on a broad collection of
experiments with reduced bias towards any individual
peptide screen or study. The semantics and relational
database are important in this process because a large
amount of data can be normalized and because sequence
similarity is not the only indicator of functional similarity.
For example, PLPP and SKSKDRYY possess similar activities even though they do not share a single residue in common [40,41].

Conclusion
Information inconsistency arising from informal semantics is always a limitation for data integration. The minimotif semantics described here, along with the data model
and its implementation, enable the computation of functional equivalence between minimotifs. This linguistic
scheme is similar to one recently suggested by Gimona
[42].
The syntax will facilitate many types of computational
analyses of minimotifs. We are now able to generate spe-

http://www.biomedcentral.com/1471-2164/10/360

cific subsets of data based on any of the 22 attributes of
minimotifs. For example, the database facilitates refining
sequence definitions similar to the recent refinement of a
sumoylation minimotif [43]. The normalized syntax will
allow exchange of data with other databases, reduce
redundancies, and provides a framework for future annotations. The syntax also facilitates minimotif classification, as done for SH3 domain binding minimotifs in this
paper.

Methods
Database Design
Our theoretical model of minimotif semantics is only useful if it is logically understood by a machine, thus the reason why we built a relational database. It is typical to
implement database relationships in ways which exceed
the complexity of the theoretical data model on which
they are based (for performance and practicality reasons).
Because many Targets can also be Minimotif containing
proteins, and the three Minimotif/Activity/Target components are only related by experimental work, many additional tables were needed to link information for these
components.

Full database documentation is provided [see Additional
file 2]. Since the most important elements of our database
are those which directly model the semantics, a mapping
between our conceptual model and its physical implementation is provided in a table in Additional file 1. The
physical model also includes many other federated data
sources which are not in the conceptual model such as the
gene alias names (ref_homologene_2_gene_alias), and
minimotif
annotation
literature
sources
(motif_source_pubmedsource) which are linked to the
ref_pubmedsource table (not shown). More information
regarding these relationships is in Additional file 2.
Additional tables in the database were used for data mining. For example, Motif_source_motif_group groups
minimotif_source records and ref_amino_acid is a table
of all amino acids. The motif table contains the minimotif
amino acid sequence and any post-translational modification to the sequence. Each minimotif is associated with
one motif_source record, which is an intersection point
for two ref_molecule records (one being the minimotif
containing protein, and one being the molecule type of
the target which the minimotif acts upon). The target is
optional depending on the annotation rule.
Each ref_molecule entry can be optionally associated with
either a RefSeq protein and/or a HomoloGene cluster, and
additionally may have a ref_domain record (which is a
federation of the NCBI Conserved Domain Database
(CDD)) [24]. These clusters are important because many
minimotif functions are conserved across species bound-
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aries, allowing us to group RefSeq proteins which serve as
minimotif targets.
Clustering of SH3 minimotifs [see Additional file 1]
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